THERAPEUTICS
Malaria vaccine was safe for infants and did not interfere with the immunogenicity of coadministered antigens
| The first 150 words of the full text of this article appear below. |
STUDY DESIGN
randomised controlled trial. ClinicalTrials.gov NCT00289185 [ClinicalTrials.gov] .
concealed.*
blinded (parents, healthcare providers, investigators, data collectors, outcome assessors, and data analysts).*
STUDY QUESTION
hospital in Bagamoyo, Tanzania.
340 infants 6–10 weeks of age (mean age 8 wks, 52% girls) who had been born at 36–42 weeks of gestation weighing
2500 g. Infants were excluded if they were born to mothers positive for HIV or hepatitis B virus, had congenital malformations, or were same-sex twins.
3 doses of the RTS,S/AS02D malaria and hepatitis B vaccine (n = 170) or a hepatitis B vaccine only (n = 170) at 8, 12, and 16 weeks of age. All infants also received vaccines against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B, normally provided by the World Health Organizations Expanded Program on Immunization (EPI).
serious adverse events (intention-to-treat population), antibody response to the EPI vaccines (non-inferiority, per-protocol population), and vaccine efficacy against malaria infection.
9 months.
90%.
MAIN RESULTS
Groups
Ö stersund Hospital and Mid Sweden University Ö stersund, Sweden
Lovisenberg Deaconal University College Oslo, Norway
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
